SCHEMBL18220271

SCHEMBL18220271

CCC(O)CNS(=O)(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N(CC)CC)ccc3c2)s1

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.36
APP P05067 1/20 0.35
ESRRG P62508 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
POLB P06746 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17120673 0.95 MAPT (0.35) MAPTAPP
SCHEMBL18220266 0.93 MAPT (0.35) MAPTAPP
SCHEMBL18220269 0.93 MAPT (0.36) MAPTAPP
SCHEMBL17120683 0.88 MAPT (0.34) MAPTAPP
SCHEMBL20306972 0.88 MAPT (0.38) MAPTAPPESRRGMEN1ALDH1A1
SCHEMBL18221503 0.86 MAPT (0.34) MAPTAPP
SCHEMBL24075810 0.86 MAPT (0.33) MAPTAPP
SCHEMBL18220159 0.85 MAPT (0.37) MAPTAPPESRRGMEN1ALDH1A1
SCHEMBL19294125 0.84 MAPT (0.36) MAPTAPPMEN1ALDH1A1POLB
SCHEMBL23134884 0.84 APP (0.40) MAPTAPPESRRGMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 MAPT 25/4885APP 1/4885ESRRG 3495/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 MAPT 25/4885APP 1/4885ESRRG 3495/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA MAPT 26/4885APP 1/4885ESRRG 3411/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA MAPT 26/4885APP 1/4885ESRRG 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.